DUPIXENT was evaluated in adult patients whose moderate-to-severe atopic dermatitis was inadequately controlled on topical therapies.1,2
mean disease duration
Clinical trials included monotherapy (Trials 1 and 2) and with concomitant TCS (Trial 3); all trials initiated with two 300 mg DUPIXENT or placebo subcutaneous injections at Week 0, and emollient background regimen was required.1,2
Skin severity at baseline
dermatitis (IGA 3)
dermatitis (IGA 4)
Not actual patients. For illustrative purposes only.
33 Mean EASI score out of 72
≈55% Mean body surface area involvement
7 on a scale of 0 to 10
Disease severity was defined by an IGA score ≥3 in the overall assessment of atopic dermatitis lesions on a severity scale of 0 to 4, an EASI score ≥16 on a scale of 0 to 72, and a minimum body surface area involvement of ≥10%.1
Primary endpoint across all 3 pivotal trials: Change from baseline to Week 16 in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and a ≥2-point improvement1
EASI, Eczema Area and Surface Index: IGA, Investigator’s Global Assessment; NRS, numerical rating scale; TCS, topical corticosteroids.
a Mean age of patients across all 3 trials was approximately 38 years.
b Weekly averaged peak pruritis NRS score (10 indicates the most severe).